Moderna, the company, manufacturing a vaccine against the COVID-19 virus, on Monday announced that the first phase of testing the vaccine on people in the United States was able to stimulate an immune response against Coronavirus and appears to be safe. The results are of a vaccine test, which was conducted on eight people, were each given two doses of the vaccine since March. After the dose, these healthy volunteers generated antibodies. At the company's laboratory, the antibodies then were thoroughly tested in the human cells and resulted in stopping the virus from multiplying. 

The amount of the said neutralized antibodies were at par with the amount found in the patients who had recovered from the Coronavirus. The Vaccine was tested as low dose, medium dose and high dose, low and medium doses had one side effect though, causing redness and soreness, where the shot was given, in just one patient. The high dose showed the best results; however further tests will be conducted on low and medium doses as firm's chief medical officer Tai Zaks said, "Lower the dose, more vaccine we'll be able to make". The second phase of the testing which involves 600 people is due to start soon and the third phase will test thousands of healthy people & is scheduled to begin from July said Moderna. 

The FDA has given permission to Moderna for further phases of testing. If all the testing goes well, then the vaccine can be made available to the general public by 2020 end or early 2021. Due to this positive announcement in pre-market trading, Moderna's stock was up by 40%.